News & Videos - ACLARIS THERAPEUTICS INC. - English

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets PR Newswire NEWARK, Del. and NANJING, China, Nov. 18, 2024 Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit...

Thinking about buying stock in KE Holdings, Ford Motor, Vertiv Holdings, Cadrenal Therapeutics, or Aclaris Therapeutics? PR Newswire NEW YORK, Jan. 22, 2024 NEW YORK , Jan. 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEKE, F, VRT, CVKD, and ACRS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BEKE:...

...

...

...

...

...

...

...

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (NYSE: ACRS) securities between May 8, 2018 and June 29, 2019 (the “Class Period”). Investors have until September 30, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action On June 20, 2019, the U.S....

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS PR Newswire NEW YORK, Sept. 26, 2019 NEW YORK , Sept. 26, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) and certain of its officers. The class action, filed in United States District Court, for the Southern...

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm PR Newswire NEW YORK, Sept. 25, 2019 NEW YORK , Sept. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris...

New York, New York--(Newsfile Corp. - September 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Aclaris stock or options between May 8, 2018 and June 20, 2019 and would like to discuss your legal rights, click here...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”) of the important September 30, 2019 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Aclaris investors under the federal securities laws. To join the Aclaris class action, go to http://www.rosenlegal.com/cases-register-1637.html or call Phillip...

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018 and June 20, 2019. Aclaris, a pharmaceutical company, identifies, develops, and commercializes therapies for dermatological and immune-inflammatory diseases. Its lead product is ESKATA, a hydrogen peroxide...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS PR Newswire NEW YORK, Aug. 24, 2019 NEW YORK , Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation concerns whether Aclaris and certain...

...

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ACRS PR Newswire NEW YORK, Aug. 2, 2019 NEW YORK , Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20 , 2019,...

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2018 and June 20, 2019, inclusive (the ''Class Period''), are...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm PR Newswire NEW YORK, July 31, 2019 NEW YORK , July 31, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action...